Clinical use of FLT3 inhibitors in acute myeloid leukemia

References

• ArberDAOraziAHasserjianRThe 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood2016127202391240527069254
   PubMed Web of Science ®Google Scholar
• PapaemmanuilEGerstungMBullingerLGenomic Classification and Prognosis in Acute Myeloid LeukemiaN Engl J Med2016374232209222127276561
   PubMed Web of Science ®Google Scholar
• NakaoMYokotaSIwaiTInternal tandem duplication of the flt3 gene found in acute myeloid leukemiaLeukemia19961012191119188946930
   PubMed Web of Science ®Google Scholar
• SmallDFLT3 mutations: biology and treatmentHematology Am Soc Hematol Educ Program200617818417124058
   PubMedGoogle Scholar
• GaleREGreenCAllenCThe impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemiaBlood200811152776278417957027
   PubMed Web of Science ®Google Scholar
• WhitmanSPArcherKJFengLAbsence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B studyCancer Res200161197233723911585760
   PubMed Web of Science ®Google Scholar
• ThiedeCSteudelCMohrBAnalysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosisBlood200299124326433512036858
   PubMed Web of Science ®Google Scholar
• DöhnerHEsteyEGrimwadeDDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood2017129442444727895058
   PubMed Web of Science ®Google Scholar
• HoADScheteligJBochtlerTAllogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITDBiol Blood Marrow Transplant201622346246926551637
   PubMed Web of Science ®Google Scholar
• HaradaYNagataYKiharaRPrognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 studyLeuk Res201866202729360622
   PubMed Web of Science ®Google Scholar
• BerensteinRClass III Receptor Tyrosine Kinases in Acute Leukemia – Biological Functions and Modern Laboratory AnalysisBiomark Insights201510Suppl 3114
   PubMedGoogle Scholar
• MackarehtschianKHardinJDMooreKABoastSGoffSPLemischkaIRTargeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitorsImmunity1995311471617621074
   PubMed Web of Science ®Google Scholar
• BöiersCBuza-VidasNJensenCTExpression and role of FLT3 in regulation of the earliest stage of normal granulocyte-monocyte progenitor developmentBlood2010115245061506820393130
   PubMed Web of Science ®Google Scholar
• TsapogasPMooneyCJBrownGRolinkAThe Cytokine Flt3-Ligand in Normal and Malignant HematopoiesisInt J Mol Sci2017186E111528538663
   PubMed Web of Science ®Google Scholar
• CarowCELevensteinMKaufmannSHExpression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemiasBlood1996873108910968562934
   PubMed Web of Science ®Google Scholar
• MizukiMSchwableJSteurCSuppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutationsBlood200310183164317312468433
   PubMed Web of Science ®Google Scholar
• LiLPilotoONguyenHBKnock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse modelBlood200811173849385818245664
   PubMed Web of Science ®Google Scholar
• HospitalMAGreenASMacielTTFLT3 inhibitors: clinical potential in acute myeloid leukemiaOnco Targets Ther20171060761528223820
   PubMed Web of Science ®Google Scholar
• JiangXBugnoJHuCTargeted Treatment of FLT3-Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand PeptidesBlood20151263784
   Web of Science ®Google Scholar
• MolicaMBrecciaMFLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosisLeuk Res201539439739925666257
   PubMed Web of Science ®Google Scholar
• LancetJEFLT3 inhibitors for acute myeloid leukemiaClin Adv Hematol Oncol201513957357526452187
   PubMedGoogle Scholar
• ChienCDSauterCTIshiiKPreclinical Development of FLT3-Redirected Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid LeukemiaBlood20161281072
   Web of Science ®Google Scholar
• NagaiKHouLLiLArsenic Trioxide Synergizes with FLT3 Tyrosine Kinase Inhibitors to Kill FLT3-ITD+ Leukemic Cells through Depressed Production and Degradation of FLT3 ProteinBlood20161281568
   Web of Science ®Google Scholar
• GrimwadeDIveyAHuntlyBJMolecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceBlood20161271294126660431
   PubMed Web of Science ®Google Scholar
• PratzKWSatoTMurphyKMStineARajkhowaTLevisMFLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AMLBlood201011571425143220007803
   PubMed Web of Science ®Google Scholar
• LevisMHow and when to use FLT3 inhibitorsClin Lymphoma Myeloma Leuk201717S18S21
   Google Scholar
• ServeHKrugUWagnerRSorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trialJ Clin Oncol201331253110311823897964
   PubMed Web of Science ®Google Scholar
• RölligCServeHHüttmannAAddition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialLancet Oncol201516161691169926549589
   PubMed Web of Science ®Google Scholar
• StoneRMMandrekarSJSanfordBLMidostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationN Engl J Med2017377545446428644114
   PubMed Web of Science ®Google Scholar
• KnapperSRussellNGilkesAA randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AMLBlood201712991143115427872058
   PubMed Web of Science ®Google Scholar
• SmithCCLasaterEALinKCCrenolanib is a selective type I pan-FLT3 inhibitorProc Natl Acad Sci U S A2014111145319532424623852
   PubMed Web of Science ®Google Scholar
• ZimmermanEITurnerDCBuaboonnamJCrenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemiaBlood2013122223607361524046014
   PubMed Web of Science ®Google Scholar
• OhanianMKantarjianHMBorthakurGEfficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+AMLBlood2016128274427932331
   PubMed Web of Science ®Google Scholar
• StoneRMCollinsRTallmanMSEffect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AMLJournal of Clinical Oncology2017357016
   Web of Science ®Google Scholar
• PratzKCherryMAltmanJKPreliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)Blood201713072228588020
   PubMed Web of Science ®Google Scholar
• SmithCCPaguiriganAJeschkeGRHeterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysisBlood20171301485828490572
   PubMed Web of Science ®Google Scholar
• KnapperSBurnettAKLittlewoodTA phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapyBlood2006108103262327016857985
   PubMed Web of Science ®Google Scholar
• DeangeloDJStoneRMHeaneyMLPhase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsBlood2006108123674368116902153
   PubMed Web of Science ®Google Scholar
• FischerTStoneRMDeangeloDJPhase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3J Clin Oncol201028284339434520733134
   PubMed Web of Science ®Google Scholar
• LevisMRavandiFWangESResults from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseBlood2011117123294330121270442
   PubMed Web of Science ®Google Scholar
• RavandiFAlattarMLGrunwaldMRPhase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationBlood2013121234655466223613521
   PubMed Web of Science ®Google Scholar
• StratiPKantarjianHRavandiFPhase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndromeAm J Hematol201590427628125530214
   PubMed Web of Science ®Google Scholar
• PerlAEAltmanJKCortesJSelective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 studyLancet Oncol2017181061107528645776
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHMKadiaTMCrenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AMLJournal of Clinical Oncology2016347008
   Web of Science ®Google Scholar
• OhanianMKantarjianHMBorthakurGEfficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AMLBlood2016128274427932331
   PubMed Web of Science ®Google Scholar
• IyerSPJethavaYKaranesCEckardtJRCollinsRSafety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AMLBlood20161283983
   Web of Science ®Google Scholar
• SchillerGJTallmanMSGoldbergSLFinal results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemiaJournal of Clinical Oncology2014327100
   Web of Science ®Google Scholar
• ChenYBLiSLaneAAPhase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemiaBiol Blood Marrow Transplant201420122042204825239228
   PubMed Web of Science ®Google Scholar
• PratzKWGojoIKarpJEProspective Study of Peri-Transplant Use of Sorafenib As Remission Maintenance for FLT3-ITD Patients Undergoing Allogeneic TransplantationBlood20151263164
   Web of Science ®Google Scholar
• LarsonRAMandrekarSJSanfordBLAn Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 MutationsBlood2017130145
   Web of Science ®Google Scholar
• SchmalbrockLKCocciardiSDolnikAClonal Evolution of FLT3-ITD Positive AML in Patients Treated with Midostaurin in Combination with Chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 TrialsBlood2017130182
   Web of Science ®Google Scholar
• StoneRMFischerTPaquetteRPhase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemiaLeukemia20122692061206822627678
   PubMed Web of Science ®Google Scholar
• RavandiFArana YiCCortesJEFinal report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemiaLeukemia20142871543154524487412
   PubMed Web of Science ®Google Scholar
• RavandiFCortesJEJonesDPhase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemiaJ Clin Oncol201028111856186220212254
   PubMed Web of Science ®Google Scholar
• FiedlerWKayserSKebenkoMA phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutationsBr J Haematol2015169569470025818407
   PubMed Web of Science ®Google Scholar
• WangESStoneRMTallmanMSWalterRBEckardtJRCrenolanibCRA Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)Blood20161281071
   Web of Science ®Google Scholar
• CooperBWKindwall-KellerTLCraigMDA phase I study of midostaurin and azacitidine in relapsed and elderly AML patientsClin Lymphoma Myeloma Leuk201515742843225776192
   PubMed Web of Science ®Google Scholar
• FiedlerWServeHDöhnerHA phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the diseaseBlood2005105398699315459012
   PubMed Web of Science ®Google Scholar
• RandhawaJKKantarjianHMBorthakurGResults of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 MutationsBlood2014124389
   Web of Science ®Google Scholar
• CortesJEKantarjianHForanJMPhase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication statusJ Clin Oncol201331293681368724002496
   PubMed Web of Science ®Google Scholar
• SchillerGJTallmanMSGoldbergSLFinal results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemiaJournal of Clinical Oncology2014327100
   Web of Science ®Google Scholar
• AbdelallWKantarjianHMBorthakurGThe Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialBlood2016128164227471233
   PubMed Web of Science ®Google Scholar